Iterum Therapeutics (NASDAQ:ITRM) Shares Down 3.4%

Iterum Therapeutics plc (NASDAQ:ITRM) traded down 3.4% during trading on Monday . The stock traded as low as $0.75 and last traded at $0.75. 17,282 shares traded hands during mid-day trading, a decline of 71% from the average session volume of 60,503 shares. The stock had previously closed at $0.78.

Iterum Therapeutics Trading Down 3.4 %

The company has a debt-to-equity ratio of 1.64, a quick ratio of 4.40 and a current ratio of 4.40. The company has a 50-day simple moving average of $0.98 and a 200 day simple moving average of $1.05. The company has a market capitalization of $9.82 million, a P/E ratio of -0.17 and a beta of 1.59.

Iterum Therapeutics (NASDAQ:ITRM) last issued its quarterly earnings results on Friday, August 11th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.15). Sell-side analysts expect that Iterum Therapeutics plc will post -3.54 earnings per share for the current year.

Institutional Trading of Iterum Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC increased its position in shares of Iterum Therapeutics by 199.1% during the second quarter. Renaissance Technologies LLC now owns 323,300 shares of the company’s stock valued at $65,000 after purchasing an additional 215,200 shares during the period. Goldman Sachs Group Inc. bought a new stake in shares of Iterum Therapeutics during the second quarter valued at approximately $61,000. Apollon Wealth Management LLC bought a new stake in Iterum Therapeutics in the second quarter valued at $214,000. Finally, Dimensional Fund Advisors LP bought a new stake in Iterum Therapeutics in the third quarter valued at $101,000. 3.39% of the stock is currently owned by institutional investors.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.